Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.33
0.00 (-0.04%)
At close: May 30, 2025, 4:00 PM
5.58
+0.25 (4.78%)
After-hours: May 30, 2025, 4:05 PM EDT
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $257.88K in the quarter ending March 31, 2025, with 103.32% growth. This brings the company's revenue in the last twelve months to $3.69M, down -39.87% year-over-year. In the year 2024, Coya Therapeutics had annual revenue of $3.55M, down -40.79%.
Revenue (ttm)
$3.69M
Revenue Growth
-39.87%
P/S Ratio
22.86
Revenue / Employee
$460,638
Employees
8
Market Cap
88.48M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
Dec 31, 2023 | 6.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
COYA News
- 14 days ago - Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Business Wire
- 17 days ago - Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update - Business Wire
- 22 days ago - Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 - Business Wire
- 22 days ago - Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors - GlobeNewsWire
- 5 weeks ago - Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
- 5 weeks ago - Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - Business Wire
- 5 weeks ago - Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - Business Wire
- 2 months ago - Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - Business Wire